Good point-- I tried to note that in the second to last section. So, with standard amounts of cryoprotectant, I guess that sufficiently long patient storage at dry ice temperatures would just result in a super thin (nanoscale) layer of ice forming on basically all the nucleation-inducing surfaces (which could then all potentially grow with rewarming), right? That sounds bad, but I don't have much intuition for exactly how bad that would be.
Yeah, sorry, I felt bad for not acknowledging that bit.
I guess that sufficiently long patient storage at dry ice temperatures would just result in a super thin (nanoscale) layer of ice forming on basically all the nucleation-inducing surfaces (which could then all potentially grow with rewarming), right?
Hmm.. that's a really good question. Off the top of my head I don't know where the actual amount of ice growth over time can be figured out. I'll keep an eye out for more info.
Trouble is, I think, that (depending on perfusion) at -80'C it's water is ...
Edited nearly a year later to clarify: dry ice cryonics probably won't work, for reasons hinted at in the post, and stated by Gav in the comments, regarding nanoscale ice crystals. It seems like there may be less of a tradeoff between fracturing and having ice crystals now than there used to be, especially if newer approaches involving e.g. cryonics with persufflation end up working well in humans.
This post is a spot-check of Alcor's claim that cryonics can't be carried out at dry ice temperatures, and a follow-up to this comment. This article isn't up to my standards, yet I'm posting it now, rather than polishing it more first, because I strongly fear that I might never get around to doing so later if I put it off. Despite my expertise in chemistry, I don't like chemistry, so writing this took a lot of willpower. Thanks to Hugh Hixon from Alcor for writing "How Cold is Cold Enough?".
Summary
More research (such as potentially hiring someone to find the energies of activation for lots of different degradative reactions which happen after death) is needed to determine if long-term cryopreservation at the temperature of dry ice is reasonable, or even preferable to storage in liquid nitrogen.
On the outside view, I'm not very confident that dry ice cryonics will end up being superior to liquid nitrogen cryonics. Still, it's very hard to say one way or the other a priori. There are certain factors that I can't easily quantify that suggest that cryopreservation with dry ice might be preferable to cryopreservation with liquid nitrogen (specifically, fracturing, as well as the fact that the Arrhenius equation doesn't account for poor stirring), and other such factors that suggest preservation in liquid nitrogen to be preferable (specifically, that being below the glass transition temperature prevents movement/chemical reactions, and that nanoscale ice crystals, which can grow during rewarming, can form around the glass transition temperature).
(I wonder if cryoprotectant solutions with different glass transition temperatures might avoid either of the two problems mentioned in the last sentence for dry ice cryonics? I just heard about the issue of nanoscale ice crystals earlier today, so my discussion of them is an afterthought.)
Motivation
Using dry ice to cryopreserve people for future revival could be cheaper than using liquid nitrogen for the same purpose (how much would using dry ice cost?). Additionally, lowering the cost of cryonics could increase the number of people who sign up for cryonics-- which would, in turn, give us a better chance at e.g. legalizing the initiation of the first phases of cryonics for terminal patients just before legal death.
This document by Alcor suggests that, for neuro and whole-body patients, an initial deposit of 6,600 or 85,438 USD into the patient's trust fund is, respectively, more than enough to generate enough interest to safely cover a patient's annual storage cost indefinitely. Since around 36% of this amount is spent on liquid nitrogen, this means that completely eliminating the cost of replenishing the liquid nitrogen in the dewars would reduce the up-front cost that neuro and whole-body patients with Alcor would pay by around 2,350 or 31,850 USD, respectively. This puts a firm upper bound on the amount that could be saved by Alcor patients by switching to cryopreservation with dry ice, since some amount would need to be spent each year on purchasing additional dry ice to maintain the temperature at which patients are stored. (A small amount could probably be saved on the cost which comes from cooling patients down immediately after death, as well).
This LW discussion is also relevant to storage costs in cryonics. I'm not sure how much CI spends on storage.
Relevant Equations and Their Limitations
Alcor's "How Cold is Cold Enough?" is the only article which I've found that takes an in-depth look at whether storage of cryonics patients at temperatures above the boiling point of liquid nitrogen would be feasible. It's a generally well-written article, though it makes an assumption regarding activation energy that I'll be forced to examine later on.
The article starts off by introducing the Arrhenius equation, which is used to determine the rate constant of a chemical reaction at a given temperature. The equation is written:
k = A * e^(-Ea/RT) (1)
Where: